Peri-procedural management of anti-platelets and anticoagulation in patients undergoing MitraClip procedure.
The MitraClip device was recently approved by the FDA for the management of severe degenerative mitral regurgitation in patients considered to be high risk for surgical repair or replacement of the mitral valve. The management of anti-platelet and anticoagulant therapy before, during, and after the MitraClip placement is not well defined given the lack of evidence from large randomized trials. In this paper, we propose practical management guidelines for using these agents.